Viruses engineered for gene therapy and the destruction of tumor cells (oncolytic viruses) are a growing medical market (~$1B by 2026) with profound implications for human health. To comply with FDA regulations, most drug products remove microbial contaminants with sterile filtration as a final step. In the case of viruses, the broad pore sizes and high internal surface areas of commercial sterile filtration membranes result in massive product loss (~80%). Consequently, GMP paradigms for the production of medical grade virus must implement aseptic practices at every step of production. SiMPore uses silicon-based manufacturing to create ultrathin (~100-400 nm thick) membranes with precision pore sizes and more than 3 orders-of-magnitude less internal surface area than conventional sterile-filters. This proposal investigates the hypothesis that these distinctive properties will enable sterile filtration of virus with less than 10% loss.
In Aim 1 we will develop and characterize ultrathin membranes with a high density of 0.2 m slit-pores. This pore size matches the average pore size of commercial sterile filters, but with a dramatic reduction in thickness and internal surface area. Functional characterization will include sieving, burst pressures, and hydraulic permeability testing.
In Aim 2, we will evaluate SiMPore membranes as sterile filters by comparing loss and capacity directly to 3 commercial sterile membrane filters. With success in Phase I, SiMPore's membranes will be scaled up from chip-based to sheet-based formats and used in diafiltration modules as final processing step in actual viral manufacturing processes during Phase II.

Public Health Relevance

The manufacture of viruses for gene therapy or as anti-cancer agents cannot use sterile filtration as a final production step because of massive titer loss (~80%) with conventional polymer membranes. SiMPore uses silicon manufacturing to produce ultrathin membranes with precise pore sizes that should enable the filtration of virus with minimal loss. This project will develop SiMPore membranes for the sterile filtration of virus and compare performance directly against three commercial membrane filters.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM128475-01
Application #
9558195
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Krepkiy, Dmitriy
Project Start
2018-03-01
Project End
2018-08-31
Budget Start
2018-03-01
Budget End
2018-08-31
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Simpore, Inc.
Department
Type
DUNS #
792264918
City
West Henrietta
State
NY
Country
United States
Zip Code
14586